Amarin | AMRN - Despesas De Vendas E Administração





Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.63B 54M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
AstraZeneca USD 5.8B 735M 2026-06
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
DBV Technologies USD 13.4M 8.14M 2026-03
GlaxoSmithKline GBP 2.19B 75M 2026-06
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06